<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34900a7b-aa04-4a10-bc35-6e304678116b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">CTEXLI</content> safely and effectively.  See full prescribing information for <content styleCode="bold">CTEXLI</content>.<br/>
      <br/>
      <content styleCode="bold">CTEXLI<sup>TM</sup> (chenodiol) tablets, for oral use</content>
      <br/>Initial U.S. Approval: <content styleCode="bold">1983</content>
   </title>
   <effectiveTime value="20250221"/>
   <setId root="015384e7-4ac5-4782-a309-e40cd1421c5b"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="116902386" root="1.3.6.1.4.1.519.1"/>
            <name>Mirum Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="fc6887d0-870e-4a79-ac6d-72c4cedfa9ba"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250221"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79378-310" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CTEXLI</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>chenodiol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0GEI24LG0J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CHENODIOL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0GEI24LG0J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHENODIOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4GFU244C4J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLCELLULOSE (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="79378-310-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250404"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA219488" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250404"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">MP;250</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_6008ec57-7c40-4ea6-a0e2-0801285400a5">
               <id root="61a1e7ea-dacf-4541-a55c-127482e7d4dc"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>CTEXLI is indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.</paragraph>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>CTEXLI is a bile acid indicated for treatment of cerebrotendinous xanthomatosis (CTX) in adults. (<linkHtml href="#ID_6008ec57-7c40-4ea6-a0e2-0801285400a5">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_560ac569-2ae8-46d3-8c14-c7d29fe4f234">
               <id root="b2e1da29-bb4b-4010-b95e-0392645d0125"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Before initiating CTEXLI, obtain baseline liver transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and total bilirubin levels in all patients. (<linkHtml href="#ID_16c914e5-bc2f-4e65-876b-e42c2e891040">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>The recommended dosage is 250 mg orally three times daily. (<linkHtml href="#ID_8e9b47f1-7204-4c43-b6ef-4ab4bcc8e209">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_16c914e5-bc2f-4e65-876b-e42c2e891040">
                     <id root="534af6a7-12a9-4c7a-829a-0b9ccd17fda1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Important Recommendation Prior to CTEXLI Treatment Initiation </title>
                     <text>
                        <paragraph>Before initiating CTEXLI, obtain baseline liver transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and total bilirubin levels in all patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3f69cba5-87c4-4288-b6b2-a6b356b535cf">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8e9b47f1-7204-4c43-b6ef-4ab4bcc8e209">
                     <id root="c5931605-3e8f-441a-b9b2-b84a37c1336d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Recommended Dosage </title>
                     <text>
                        <paragraph>The recommended dosage of CTEXLI is 250 mg administered orally three times daily.</paragraph>
                        <paragraph>Administer CTEXLI with or without food. Swallow tablets whole.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Missed Dose</content>
                        </paragraph>
                        <paragraph>If a dose of CTEXLI is missed, advise the patient to skip the missed dose and to resume taking the prescribed dose at the next scheduled time. Patients should not take a double dose.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4b1d77bd-e662-4a49-915f-9b424e195c7c">
                     <id root="a7345346-b5b9-4e28-a670-377408d5706d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3  Administration Modification and Monitoring </title>
                     <text>
                        <paragraph>If liver transaminase (ALT, AST) levels are elevated &gt; 3 times the upper limit of normal (ULN) or total bilirubin level is &gt;2 times ULN, interrupt treatment with CTEXLI until the levels have returned to baseline values. Monitor liver transaminase and total bilirubin levels yearly and as clinically indicated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3f69cba5-87c4-4288-b6b2-a6b356b535cf">5.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b8435494-99c6-4870-b02a-ac90bff0b050">
               <id root="68c9b9b3-cf2c-4c28-ae6a-2048784c0567"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Tablets: 250 mg of chenodiol as white film-coated tablets imprinted with “MP” on one side and "250" on the other side.</paragraph>
               </text>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>CTEXLI tablets: 250 mg. (<linkHtml href="#ID_b8435494-99c6-4870-b02a-ac90bff0b050">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_e5b848a9-2e0e-4fb5-8666-1e2d885c1098">
               <id root="f066e071-b458-498e-b866-aa7b1360acf2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#ID_e5b848a9-2e0e-4fb5-8666-1e2d885c1098">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_4acc1b53-db6d-4465-918e-fb94effa5796">
               <id root="7c829069-b236-480b-a11e-a14e8973e38f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Hepatotoxicity</content>: Obtain baseline liver transaminase and total bilirubin levels in all patients and monitor yearly and as clinically indicated. Interrupt treatment until the levels have returned to baseline values. For persistent or recurrent liver test abnormalities, consider discontinuing CTEXLI. (<linkHtml href="#ID_3f69cba5-87c4-4288-b6b2-a6b356b535cf">5.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_3f69cba5-87c4-4288-b6b2-a6b356b535cf">
                     <id root="289ab907-3f70-4336-88a1-23b6e35d5aca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hepatotoxicity </title>
                     <text>
                        <paragraph>Chenodiol, including CTEXLI, has been associated with hepatotoxicity <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_1d1d6819-8144-4434-93a5-f40167c4cd75">6</linkHtml>)]</content>. In Trial 1, one CTEXLI-treated patient (7%) had increased ALT levels &gt; 3 times ULN, which led to treatment interruption. Patients with pre-existing liver disease or bile duct abnormalities may be at higher risk for hepatotoxicity during treatment with CTEXLI. Published reports suggest patients who are poor sulfators of lithocholic acid are more likely to develop chenodiol-induced serum aminotransferase elevations <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_4d06576e-2161-42e4-92b4-dfb4627e81c1">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Obtain baseline liver transaminase (ALT, AST) and total bilirubin levels in all patients prior to treatment initiation with CTEXLI. If liver transaminase levels are elevated &gt; 3 times ULN or total bilirubin level is &gt;2 times ULN, interrupt treatment with CTEXLI until the levels have returned to baseline values. Monitor liver transaminase and total bilirubin levels yearly and as clinically indicated. For persistent or recurrent liver test abnormalities, consider discontinuing CTEXLI.</paragraph>
                        <paragraph>Inform the patient of the symptoms of hepatotoxicity (e.g., abdominal pain, bruising, dark-colored urine, fatigue, bleeding, jaundice, nausea, and pruritus). If clinical signs and symptoms consistent with hepatotoxicity occur, have the patient discontinue CTEXLI immediately.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1d1d6819-8144-4434-93a5-f40167c4cd75">
               <id root="fbb17023-6243-4844-b5b6-e42b9d92e367"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reaction is described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3f69cba5-87c4-4288-b6b2-a6b356b535cf">5.1</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (incidence &gt; 14%) are diarrhea, headache, abdominal pain, constipation, hypertension, muscular weakness, and upper respiratory tract infection. (<linkHtml href="#ID_42c4a161-1b2a-4678-966b-d83276c8d5ec">6.1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Mirum Pharmaceuticals at 1-855-MRM-4YOU</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_42c4a161-1b2a-4678-966b-d83276c8d5ec">
                     <id root="c82cbd67-d5fc-4a9a-ab3d-307f107529a5"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of CTEXLI was evaluated in a randomized, double blind, placebo-controlled, 2-period, 2-treatment crossover trial in 14 patients (16 to 55 years of age) with CTX (Trial 1). CTEXLI is not approved for use in pediatric patients. The dosage of CTEXLI was 250 mg orally three times a day <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_fdac1a41-5e0c-415e-a932-ab62d96868c1">14</linkHtml>)].</content> The mean (SD) chenodiol exposure during Trial 1 was 139.1 (26.7) days.</paragraph>
                        <paragraph>The most common adverse reactions which occurred in two or more patients (<content styleCode="underline">&gt;</content>14%) during CTEXLI treatment (including the two 8-week open-label treatment periods) were diarrhea (36%), headache (21%), and abdominal pain (including abdominal pain upper) (14%), constipation (14%), hypertension (14%), muscular weakness (14%), and upper respiratory tract infection (14%).</paragraph>
                        <paragraph>In Trial 1, one CTEXLI-treated patient (7%) had increased ALT levels &gt; 3x ULN, which led to treatment interruption.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fcec9e35-6a58-4aa5-815d-5250d18fc729">
                     <id root="1bbfa8fb-2f83-4b2f-8e84-344b20aa2d45"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of chenodiol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Hepatobiliary Disorders: </content>Hepatotoxicity<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID_3f69cba5-87c4-4288-b6b2-a6b356b535cf">5.1</linkHtml>)]</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Immune System Disorders: </content>Hypersensitivity reactions such as facial swelling, pruritus, rash, urticaria.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3b30eee5-7d1f-4c7b-b28d-633832eee53a">
               <id root="1fbb336d-9f55-4592-8940-6d6c7328b75f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Bile acid sequestering agents and aluminum-based antacids: Avoid concomitant use with CTEXLI. (<linkHtml href="#ID_63eddc59-643f-4ce4-9311-14ffe08fbc15">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Coumarin and its derivatives: Monitor prothrombin time and adjust dosage accordingly. (<linkHtml href="#ID_3e9afaf4-bb7c-415f-9a9a-bf47d4ba3542">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_63eddc59-643f-4ce4-9311-14ffe08fbc15">
                     <id root="f236c0a4-050d-40ac-afc8-796f8ec9db9f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1  Effect of Other Drugs on CTEXLI </title>
                     <text>
                        <paragraph>Co-administration of bile acid sequestering agents, such as cholestyramine and colestipol, or aluminum-based antacids may decrease absorption of CTEXLI in the intestine and may result in decreased efficacy of CTEXLI. Avoid concomitant use of bile acid sequestering agents or aluminum-based antacids with CTEXLI.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3e9afaf4-bb7c-415f-9a9a-bf47d4ba3542">
                     <id root="29f5053a-06b4-4518-980d-bffee91daaed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2  Effect of CTEXLI on Other Drugs </title>
                     <text>
                        <paragraph>Due to potential hepatotoxicity, CTEXLI may affect the pharmacodynamics of coumarin and its derivatives, causing unexpected prolongation of the prothrombin time and hemorrhage. If concomitant use of CTEXLI with coumarin or its derivatives is unavoidable, monitor prothrombin time. Adjust the dosage of coumarin or its derivatives in accordance with its approved product labeling.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_85dceefa-e9f0-415b-874f-fd1960c910da">
               <id root="b49d563e-d32f-4be2-9d9f-b8d432fe427f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250221"/>
               <component>
                  <section ID="ID_a57a8b21-47e5-4aaa-9b90-7cfec7f818db">
                     <id root="4e217319-42cc-438e-9fc1-f22bb1fb9b84"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from published case reports over decades of use with chenodiol during pregnancy have not identified an increased risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Serious hepatic, renal and adrenal lesions occurred in fetuses of female Rhesus monkeys treated at doses 1 to 2 times the recommended human dose based on body surface area (mg/m<sup>2</sup>). Hepatic lesions also occurred at doses comparable to the human dose based on body surface area in neonatal baboons born to mothers administered chenodiol during pregnancy (<content styleCode="italics">see Data</content>). The animal study findings have not been demonstrated with human use.</paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Hepatic lesions were reported in neonatal baboons whose mothers had received 18 to 38 mg/kg of chenodiol throughout pregnancy (0.6 to 1.4 times the recommended human dose based on body surface area). Serious hepatic, renal and adrenal lesions were also reported in fetuses of female Rhesus monkeys given 60 to 90 mg/kg/day from GD 21-45 of pregnancy (1 to 2 times the recommended human dose based on body surface area). Non-human primates form sulfate conjugates of the known hepatotoxic bacterial metabolite of chenodiol, lithocholic acid, to a lesser extent than reported in humans, which may exaggerate the toxicity of orally dosed chenodiol compared to humans. However, there is also evidence that the hepatobiliary toxicity is partly due to the parent drug, chenodiol.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1c2d95df-89cf-439e-87a5-4fe0b2fcf9c3">
                     <id root="87e934cf-2033-44b7-9a7c-00cb7dae3151"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of chenodiol in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CTEXLI and any potential adverse effects on the breastfed infant from CTEXLI or the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_09e70485-168e-4fc6-8eb2-473199d8254b">
                     <id root="1cb3043c-a694-40ae-bfc5-646642309eec"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of CTEXLI for the treatment of CTX have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_27c54b7e-1311-4e81-916d-b55a493d80f0">
                     <id root="46e6df53-012e-4b66-9c15-003b688c1021"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Trial 1 of CTEXLI in patients with CTX did not include patients aged 65 years and older.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f900fce6-393e-4466-82b4-14050fa989f7">
               <id root="e5ab0ab5-4cb5-4c0c-ab15-3f9e4aa00843"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Cases of intentional overdose with chenodiol have been reported: one patient consumed 3 g to 4.5 g of chenodiol and another patient consumed 30 g of chenodiol. Clinical manifestations experienced by these patients included nausea, dizziness, and diarrhea.</paragraph>
                  <paragraph>In the event of an overdose, discontinue CTEXLI, monitor the patient, and institute general supportive measures if needed.</paragraph>
               </text>
               <effectiveTime value="20250221"/>
            </section>
         </component>
         <component>
            <section ID="ID_5bcdfc3c-18bc-4068-9656-079d4601d63d">
               <id root="705e89d9-cedc-4967-bac7-c299e766262c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>CTEXLI (chenodiol) is a bile acid. Chenodiol is a bitter-tasting, white powder consisting of crystalline and amorphous particles that are freely soluble in methanol, acetone and acetic acid, and practically insoluble in water.</paragraph>
                  <paragraph>The chemical name of chenodiol is 3α,7α-dihydroxy-5-β-cholan-24-oic acid. The molecular formula is C<sub>24</sub>H<sub>40</sub>O<sub>4</sub> and the molecular weight is 392.58 g/mol. The chemical structure is:</paragraph>
                  <renderMultiMedia ID="id110101271" referencedObject="E3314196-5518-43E8-A45B-22BBDABD26E5"/>
                  <paragraph>Each CTEXLI tablet contains 250 mg of chenodiol. Inactive ingredients are magnesium stearate, microcrystalline cellulose, pregelatinized starch, silicon dioxide, and sodium starch glycolate. The thin-film coating contains opadry YS 2 7035 (consisting of methylcellulose and glycerin) and sodium lauryl sulfate.</paragraph>
               </text>
               <effectiveTime value="20250221"/>
               <component>
                  <observationMedia ID="E3314196-5518-43E8-A45B-22BBDABD26E5">
                     <text>Chenodiol chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_929d77da-d227-431a-b99e-1b57d19b4353">
               <id root="4dfcf055-e1cf-476b-b4b0-96f1244798e3"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250221"/>
               <component>
                  <section ID="ID_955ba63a-a88f-49f1-908b-55cf7b8d6cb3">
                     <id root="d257a7f4-19b2-4e71-8f13-cccd0cec7247"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Endogenous chenodiol (chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. In CTX, the major bile acid synthesis pathways are disrupted due to partial or total deficiency in sterol 27-hydroxylase encoded by the CYP27A1 gene.</paragraph>
                        <paragraph>CTEXLI may act to replace deficient levels of the endogenous bile acid chenodeoxycholic acid in patients with CTX. Increased chenodiol levels in the enterohepatic bile acid pool restore the activation of farnesoid X receptor (FXR) and downregulate CYP7A1 leading to suppression and reduction of atypical bile acids and bile alcohols including cholestanol and 23S-pentol.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_613a6621-d463-43fc-b79d-2c98e4f3b577">
                     <id root="342a29c8-4c40-4cda-8f68-8b4ebdb3a039"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>In Trial 1, plasma cholestanol and urine 23S-pentol concentrations were elevated in patients with CTX. Treatment with CTEXLI resulted in reductions of plasma cholestanol and urine 23S-pentol concentrations in the 8-week run-in open label treatment period. Continued treatment with CTEXLI for 4 weeks in the double-blind treatment period resulted in the maintenance of low levels of urine 23S-pentol and additional reductions of plasma cholestanol <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_fdac1a41-5e0c-415e-a932-ab62d96868c1">14</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4d06576e-2161-42e4-92b4-dfb4627e81c1">
                     <id root="32df1199-fb4f-4807-9355-0506c7525ecf"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>In CTX patients, the geometric mean (%CV) maximum plasma concentration (C<sub>max</sub>), trough plasma concentration (C<sub>trough</sub>), and area under the plasma concentration-time curve (AUC<sub>0-8h</sub>) of chenodiol at steady state following the recommended dosage (250 mg administered orally three times daily) were 3.7 mcg/mL (60%), 0.7 mcg/mL (90%), and 12.5 mcg*h/mL (60%), respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The median (range) T<sub>max</sub> of chenodiol following an oral administration in CTX patients was 3 (0.5‑8) hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Due to first-pass hepatic clearance, the body pool of chenodiol resides mainly in the enterohepatic circulation. The apparent volume of distribution of chenodiol at steady-state was 0.36 L/kg. The plasma protein binding of chenodiol was approximately 98%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The geometric mean total apparent clearance of chenodiol in CTX patients was 20 L/h.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Chenodiol is well absorbed from the small intestine and taken up by the liver where it is converted to its taurine and glycine conjugates and secreted into the bile along with other endogenous bile acids in the enterohepatic circulation. Chenodiol that escapes to the colon is converted by bacterial action to lithocholic acid. Humans have the capacity to form sulfate conjugates of lithocholic acid. About 80% of the lithocholate is excreted in the feces and the remainder is absorbed and converted in the liver to its poorly absorbed sulfolithocholyl conjugates.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Conjugated chenodiol is either reabsorbed in the terminal ileum, deconjugated before excretion, or decomposed by bacteria to lithocholic acid.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>Based on <content styleCode="italics">in vitro</content> studies, chenodiol and its glyco- and tauro- conjugates are not expected to inhibit CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4, or induce CYPs 1A2 or 2B6 at the recommended dose of chenodiol of 250 mg TID. Chenodiol and its tauro- conjugate may upregulate CYP3A4 mRNA <content styleCode="italics">in vitro. </content>The clinical significance of this upregulation is unknown.</paragraph>
                        <paragraph>The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and <content styleCode="italics">in vitro</content> studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a097a7ea-3a0d-47f6-a635-8a7824f4fdbd">
               <id root="5c2cbe23-b49c-4860-924e-78b449f12879"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250221"/>
               <component>
                  <section ID="ID_8cf362f6-53ff-429d-b679-5f53478184df">
                     <id root="0c44d47a-f6a4-470c-99a9-9f2eb5e70ac1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>A two-year oral study of chenodiol in rats did not show a carcinogenic potential at the tested levels of 15 to 60 mg/kg/day (0.2 to 0.6 times the recommended human dose based on body surface area). In additional long-term studies, chenodiol given at oral doses up to 600 mg/kg/day in rats (6 times the recommended human dose based on body surface area), and 1000 mg/kg/day in mice (5 times the recommended human dose based on body surface area) induced benign and malignant liver cell tumors in female rats and cholangiomas in female rats and male mice. Two-year studies of lithocholic acid (a major metabolite of chenodiol) in mice (125 to 250 mg/kg/day, equivalent to 0.7 to 1.4 times the recommended human dose based on body surface area) and rats (250 and 500 mg/kg/day, equivalent to 3 to 5 times the recommended human dose based on body surface area) found it not to be carcinogenic. The dietary administration of lithocholic acid to chickens is reported to cause hepatic adenomatous hyperplasia.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_40b9dd33-3cff-4c00-a392-5c1d225d3aeb">
                     <id root="49c3cb4e-e2d6-409c-b384-a5ee426acfe9"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology </title>
                     <text>
                        <paragraph>Chenodiol caused hepatobiliary toxicity (e.g., cholestasis) in many animal species, including rodents, non-rodents, and non-human primates at doses close to the human dose. Less efficient sulfation of the chenodiol metabolite, lithocholic acid, in non-human primates compared to humans is thought to cause the hepatobiliary toxicity of orally dosed chenodiol. However, there is evidence that the hepatobiliary toxicity is partly due to the parent drug, chenodiol.</paragraph>
                     </text>
                     <effectiveTime value="20250221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_fdac1a41-5e0c-415e-a932-ab62d96868c1">
               <id root="e8c03203-b53f-49b0-b8b1-674d5ccadbc0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>The efficacy of CTEXLI for the treatment of patients with CTX was evaluated in Trial 1, which was a randomized, double-blind, placebo controlled, 2-period with 2-treatment crossover trial in patients ≥16 years of age (NCT 04270682).</paragraph>
                  <paragraph>In Trial 1, 14 patients were enrolled and 13 patients were randomized and treated in a crossover withdrawal design to receive either CTEXLI 250 mg or placebo orally three times daily for 4 weeks during 2 double-blind treatment periods. The study also included treatment with CTEXLI 250 mg three times daily during an 8 week run-in period and an 8-week open label period in between the 2 double-blind withdrawal periods. The total duration of study treatment was 24 weeks.</paragraph>
                  <paragraph>Of the 13 randomized patients, 62% were male and 39% were female. The baseline median age was 42 years (16-55) and median age at diagnosis was 35 years (15-55). CTEXLI is not approved for use in pediatric patients. The patient population consisted of 62% White, 15% Asian, and 23% Other (In the Other racial group, there was one patient who reported both White and Black). Ethnicity consisted of 15% Hispanic or Latino, 54% not Hispanic or Latino, and 31% unknown.</paragraph>
                  <paragraph>Plasma cholestanol and urine 23S-pentol were assessed at multiple time points as shown in <linkHtml href="#Figure_1">Figure 1</linkHtml>. For plasma cholestanol, the estimated mean change from baseline at day 29 was -2.3 µg/mL when patients continued CTEXLI treatment and 6.2 µg/mL when patients received placebo. The estimated treatment difference was -8.5 µg/mL (95% CI: -13.2, -3.9) (<linkHtml href="#_Ref191385162">Table 1</linkHtml>). For urine 23S-pentol, the estimated mean change from baseline at day 29 was 185 ng/mL when patients continued CTEXLI treatment and 29506 ng/mL when patients received placebo. The estimated treatment difference was -29321 ng/mL (95% CI: -45701, -12941).</paragraph>
                  <paragraph ID="Figure_1">
                     <content styleCode="bold">
                        <content styleCode="underline">Figure 1: Mean (SE) of Observed Plasma Cholestanol by Treatment Sequence (All Randomized Patients)</content>
                     </content>
                  </paragraph>
                  <renderMultiMedia ID="id291721897" referencedObject="ID_2152a98c-e400-434a-99be-d4e022c9f4f4"/>
                  <paragraph>DB = double-blind. Solid line represents treatment with CTEXLI and dashed line represents treatment with placebo. The mean values of plasma cholestanol at baselines and end of each DB period are annotated in the figure.</paragraph>
                  <table ID="_Ref191385162" width="100%">
                     <caption>Table 1: Summary Results for Plasma Cholestanol and Urine 23S Pentol</caption>
                     <col width="15%"/>
                     <col width="40%"/>
                     <col width="22%"/>
                     <col width="23%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="4" valign="top">For each study treatment (placebo or CTEXLI), the mean value at Baseline was calculated as the mean of the measurements obtained prior to receiving the study treatment during the double-blind study duration; and the mean value at Day 29 was calculated as the mean of the measurements at Day 29 at the end of the study treatment.<br/>For each patient at each visit, the measurement of urine 23S-pentol was calculated as the geometric mean of first 3 morning void urine samples collected within 5 days prior to the visit.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td rowspan="5" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Plasma Cholestanol (µg/mL)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Mean (SD)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">CTEXLI<br/>(N = 13)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N = 13)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>   Baseline</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>10.8 (10.0)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>8.8 (7.8)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>   Day 29</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>8.5 (7.0)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>15.1 (8.8)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>   Change from Baseline at Day 29</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>-2.3 (3.9)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>6.2 (5.6)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>   Treatment Difference</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>-8.5 (95% CI: -13.2, -3.9)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="4" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Urine 23S- Pentol (ng/mL)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>   Baseline</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>1811 (1693)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>1773 (1940)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>   Day 29</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>1996 (1341)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>31279 (27595)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>   Change from Baseline at Day 29</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>185 (1479)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>29506 (27257)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>   Treatment Difference</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>-29321 (95% CI: -45701, -12941)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250221"/>
               <component>
                  <observationMedia ID="ID_2152a98c-e400-434a-99be-d4e022c9f4f4">
                     <text>Figure 1: Mean (SE) of Observed Plasma Cholestanol by Treatment Sequence (All Randomized Patients)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_92db4154-fc79-4298-ae17-a9752b06e65f">
               <id root="f2408b02-08b8-4771-a3c0-4bc92239091d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>CTEXLI (chenodiol) tablets are supplied as 250 mg white film-coated tablets imprinted with “MP” on one side and "250" on the other side.</paragraph>
                  <paragraph>NDC 79378-310-90: 100 count bottle</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store CTEXLI at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250221"/>
            </section>
         </component>
         <component>
            <section ID="ID_2d179bb0-7964-45a0-8317-086723d2c7e0">
               <id root="40735aa0-ae3d-43cb-8ff1-55063246cd8c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Inform the patient of the symptoms of hepatotoxicity (e.g., abdominal pain, bruising, dark-colored urine, fatigue, bleeding, jaundice, nausea, and pruritus). Instruct the patient to discontinue CTEXLI immediately and seek medical care should symptoms occur<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID_3f69cba5-87c4-4288-b6b2-a6b356b535cf">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                     <br/>Manufactured for:<br/>Mirum Pharmaceuticals, Inc.<br/>Foster City, CA 94404</paragraph>
                  <paragraph>© 2025 Mirum Pharmaceuticals, Inc.<br/>CTEXLI<sup>™</sup> is a pending trademark of Mirum Pharmaceuticals, Inc.</paragraph>
               </text>
               <effectiveTime value="20250221"/>
            </section>
         </component>
         <component>
            <section ID="ID_3074e55b-80da-4fb6-8953-7b98b21f991b">
               <id root="6ffcd72d-498b-440e-991f-3e037d23604f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id-1048374722" referencedObject="ID_3becdf9a-ae7c-4099-8c40-1921df206946"/>
                  <paragraph>QR 2D;<br/>NDC: 79378-310-90;<br/>GTIN: XXXXXXXXXXXXXX;<br/>LOT: XXXXXX;<br/>EXP: YYYY-MM-DD;</paragraph>
                  <paragraph>NDC 79378-310-90;</paragraph>
                  <paragraph>Ctexli; (chenodiol); tablets; 250 mg; For oral use; 100 Tablets; Rx only;</paragraph>
                  <paragraph>Recommended Dosage: see Prescribing Information.</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.</paragraph>
                  <paragraph>Manufactured for<br/>Mirum Pharmaceuticals, Inc.<br/>Foster City, CA 94404</paragraph>
               </text>
               <effectiveTime value="20250221"/>
               <component>
                  <observationMedia ID="ID_3becdf9a-ae7c-4099-8c40-1921df206946">
                     <text>Ctexli 250 mg tablets bottle label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>